title: Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies.
abstract: Imatinib therapy remains the gold standard for treatment of chronic myeloid leukemia; however, the acquired resistance to this therapeutic agent in patients has urged the scientists to devise modalities for overcoming this chemoresistance. For this purpose, initially therapeutic agents with higher tyrosine kinase activity were introduced, which had the potential for inhibiting even mutant forms of Bcr-Abl. Furthermore, coupling imatinib with peroxisome proliferator-activated receptor ligands also showed beneficial effects in chronic myeloid leukemia cell proliferation. These combination protocols inhibited cell growth and induced apoptosis as well as differentiation in chronic myeloid leukemia cell lines. In addition, peroxisome proliferator-activated receptors ligands increased imatinib uptake by upregulating the expression of human organic cation transporter 1. Taken together, peroxisome proliferator-activated receptors ligands are currently being considered as novel promising therapeutic candidates for chronic myeloid leukemia treatment, because they can synergistically enhance the efficacy of imatinib. In this article, we reviewed the potential of peroxisome proliferator-activated receptors ligands for use in chronic myeloid leukemia treatment. The mechanism of action of these therapeutics modalities are also presented in detail.
authors: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.|Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.|Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.|Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Bahman
authors: B
authors: Yousefi
authors: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.|Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Nasser
authors: N
authors: Samadi
authors: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Behzad
authors: B
authors: Baradaran
authors: Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.|Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Vahid
authors: V
authors: Shafiei-Irannejad
authors: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.|Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Nosratollah
authors: N
authors: Zarghami
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D027682:Cation Transport Proteins / Q000378:metabolism; D004357:Drug Synergism; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate / Q000819:agonists / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: cancer; chemotherapy; chronic myeloid leukemia; peroxisome proliferator-activated receptors